Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. (Nasdaq: BEAM) generates frequent news as a biotechnology company developing precision genetic medicines through base editing. News about BEAM stock often centers on clinical data readouts, regulatory designations and strategic updates across its hematology and liver-targeted genetic disease franchises.
Investors following BEAM news can expect detailed updates on risto-cel (formerly BEAM-101), an investigational ex vivo base editing cell therapy for sickle cell disease with severe vaso-occlusive crises. The company regularly reports safety and efficacy data from the BEACON Phase 1/2 trial, including measures such as fetal hemoglobin induction, reductions in sickle hemoglobin, engraftment times and markers of hemolysis, as well as designations like RMAT and orphan drug status from the U.S. Food and Drug Administration.
Another major source of headlines is BEAM-302, Beam’s liver-targeting program for alpha-1 antitrypsin deficiency (AATD). Company press releases describe Phase 1/2 trial progress, dose exploration, evidence of in vivo genetic correction of a disease-causing mutation, restoration of functional alpha-1 antitrypsin and regulatory interactions, including RMAT designation, orphan drug designation and participation in the FDA’s CDRP program.
Additional BEAM news items highlight developments in BEAM-301 for glycogen storage disease type Ia, the ESCAPE platform and BEAM-103 antibody, targeted lipid nanoparticle delivery research, financial results, cash runway commentary and participation in scientific and investor conferences. Coverage may also reference Beam’s equity stake in Orbital Therapeutics and the impact of Orbital’s acquisition by Bristol Myers Squibb, as disclosed by the company.
For readers tracking BEAM, this news feed provides ongoing insight into Beam’s clinical milestones, regulatory pathways, platform evolution and corporate transactions that shape the outlook for its precision genetic medicines pipeline.
Beam Therapeutics (Nasdaq: BEAM) announced NEJM publication of interim Phase 1/2 BEACON data for risto-cel in sickle cell disease on April 1, 2026. Data from 31 patients (follow-up 0.3–20.4 months) show mean HbF >60%, mean HbS 40%, no investigator-reported severe VOCs post-engraftment, median 1 cell collection, median 2.9 months to product release, median 4.5 months to dosing. Beam expects a U.S. BLA submission as early as year-end 2026; risto-cel holds orphan drug and RMAT designations and is in the FDA CDRP program.
Beam Therapeutics (Nasdaq: BEAM) reported updated Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency showing a well-tolerated safety profile and robust biomarker responses supporting pivotal advancement.
Key findings: 60 mg produced mean steady-state total AAT of 16.1 µM, >94% M-AAT composition, ~84% reduction in Z-AAT, and all patients above the 11 µM protective threshold; pivotal cohort expected H2 2026.
Beam Therapeutics (Nasdaq: BEAM) reported Q4 and full-year 2025 results, noted a strengthened balance sheet with $1.25B in cash and marketable securities, and announced a new liver-targeted program BEAM-304 for phenylketonuria (PKU) with an IND expected in 2026.
Beam secured a $500M senior secured facility with Sixth Street, expects a minimum $200M draw, and reiterated plans for a potential BLA submission for risto-cel as early as year-end 2026 and BEAM-302 pivotal next steps in Q1 2026.
Beam Therapeutics (Nasdaq: BEAM) secured a $500 million senior secured credit facility with Sixth Street to support the anticipated commercial launch of ristoglogene autogetemcel (risto-cel) in sickle cell disease. $100 million funded at close; up to $300 million tied to clinical, regulatory, and commercial milestones; plus a $100 million option. The seven-year facility matures in early 2033, bears ~10% annual interest, requires no scheduled amortization, is secured by first‑priority liens on substantially all assets, and includes mandatory prepayments from certain extraordinary proceeds.
Beam Therapeutics (Nasdaq: BEAM) will host an investor webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET to announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program.
The live webcast will be available in the investor section of the company's website and will be archived for 60 days after the presentation.
Beam Therapeutics (Nasdaq: BEAM) reported Q3 2025 results and clinical progress. Cash, cash equivalents and marketable securities were $1.1 billion as of Sept 30, 2025, with a cash runway expected into 2028. The company advanced multiple programs: expanded dosing in Part A and dose escalation in Part B of BEAM-302 (AATD), first patient dosed in Part B, BEAM-103 first healthy volunteer dosed, and BEACON (BEAM-101) data accepted for ASH presentation. BEAM-101 received RMAT designation. Q3 R&D was $109.8M, G&A $26.7M, and net loss $112.7M (‑$1.10/sh).
Beam Therapeutics (Nasdaq: BEAM) outlined 2026 strategic priorities for its liver-targeted genetic disease and hematology franchises and announced an extended operating runway. Key regulatory and clinical milestones include FDA alignment on a potential accelerated approval pathway for BEAM-302 in AATD based on 12-month biomarkers, a planned BLA submission for risto-cel as early as year-end 2026, and an expected disclosure of a new liver-targeted program in H1 2026. Beam estimates $1.25 billion in cash and marketable securities as of Dec 31, 2025, supporting operations into 2029.
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 5:15 p.m. PT in San Francisco.
The presentation will be available via a live webcast on the company's investor website at www.beamtx.com and the webcast will be archived for 60 days after the presentation.
Beam Therapeutics (Nasdaq: BEAM) reported updated BEACON Phase 1/2 data for ristoglogene autogetemcel (risto-cel) in 31 adults and adolescents with severe sickle cell disease (data cut-off Aug 6, 2025; follow-up 0.3–20.4 months).
Key results: mean HbF >60%, mean HbS <40%, durable editing (peripheral editing 67.4% at Month 6; 72.8% at Month 12), median 1 stem cell collection cycle (median 3 total collection days), median neutrophil engraftment 17.5 days and platelet engraftment 19 days, and no investigator-reported severe VOCs post-engraftment. One patient died 4 months post-infusion; investigator attributed death likely to busulfan conditioning.
Beam Therapeutics (Nasdaq: BEAM) announced that company management will participate in a fireside chat at the 2025 Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 3:30 p.m. GMT in London.
The event will be available via a live webcast in the company's investor section at www.beamtx.com and the webcast will be archived for 60 days following the presentation.